NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
Trending
IranRegionalMilitaryCrisisStrikesIranianMarchPowerGulfOperationsTargetsMarketGovernmentTimelineEuropeanStatesTrumpDigestDiplomaticCoalitionProtestsFlightRoutesFaces
IranRegionalMilitaryCrisisStrikesIranianMarchPowerGulfOperationsTargetsMarketGovernmentTimelineEuropeanStatesTrumpDigestDiplomaticCoalitionProtestsFlightRoutesFaces
All Articles
STAT+: Trump’s drive to get Europe to pay more for drugs creates uncertainty for countries, patients
STAT News
Published about 5 hours ago

STAT+: Trump’s drive to get Europe to pay more for drugs creates uncertainty for countries, patients

STAT News · Mar 2, 2026 · Collected from RSS

Summary

President Trump's demand that wealthy countries in Europe spend more on drugs so the U.S. can pay less has introduced uncertainty across the continent.

Full Article

Pharma is also eager to see the region increase spending on medicines Adobe Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — President Trump has for a year demanded that wealthy countries in Europe spend more on medicines so the U.S. can pay less. His campaign has introduced a new period of uncertainty across the continent. While there’s little evidence that the prices of medications in Europe have yet been jacked up, countries are facing questions about whether drugmakers will try to charge more and how strained health systems will respond. There are also questions about what it could mean for access to medicines for patients, with the industry openly threatening to withhold drugs from markets that won’t meet their demands for higher prices — or, in pharmaceutical parlance, to properly value innovation. Trump’s drive to even out the price of medicines among countries also pokes at a tricky question when trying to compare drug prices — namely, how much a drug costs in the first place. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Europe Correspondent Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71.


Share this story

Read Original at STAT News

Related Articles

STAT News19 minutes ago
STAT+: Pharmalittle: We’re reading about Trump’s MFN deals, 340B program controversies, and much more

The most-favored nation drug pricing deals the Trump administration reached with 16 drugmakers end after three years in some cases, according to SEC filings

STAT Newsabout 2 hours ago
STAT+: UniQure plans to seek approval for Huntington’s therapy still blocked by FDA

UniQure said plans to seek approval for its Huntington’s disease treatment with the FDA remain blocked.

STAT Newsabout 5 hours ago
Opinion: I analyzed 6 months of Reddit discussion about at-home ketamine therapy. The findings alarmed me

“Telehealth ketamine has crossed the line from innovation to abdication of care,” writes Michael Alvear.

STAT Newsabout 5 hours ago
Opinion: Cannabis has become more legal. It’s time to update laws around use by pregnant people

It’s time to rethink punitive policies around cannabis use by people who are pregnant.

STAT Newsabout 5 hours ago
A titan of vaccine development sees his field’s achievements slip away

Stanley Plotkin, the 93-year-old "godfather of vaccines," is watching his field’s achievements slip away.

STAT Newsabout 5 hours ago
STAT+: How can HHS drive clinical AI adoption? The industry wish list is starting to take shape

What leading health tech firms and AI startups want HHS to do to speed up clinical AI adoption.